| Not Yet Recruiting | Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones NCT06982222 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non- NCT07012031 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Not Yet Recruiting | SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer NCT07322341 | University of Washington | Phase 2 |
| Not Yet Recruiting | Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic St NCT06943664 | Roswell Park Cancer Institute | Phase 2 |
| Recruiting | GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cel NCT07017829 | Roswell Park Cancer Institute | Phase 2 |
| Not Yet Recruiting | Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tum NCT07405086 | OHSU Knight Cancer Institute | Phase 2 |
| Recruiting | Photon Craniospinal Irradiation for the Treatment of Leptomeningeal Disease Secondary to Breast Cancer or Non- NCT06910761 | City of Hope Medical Center | Phase 2 |
| Withdrawn | Cemiplimab for the Treatment of Untreated Brain Metastases From PD-L1 >= 50% Non-Small Cell Lung Cancer NCT05840770 | City of Hope Medical Center | Phase 2 |
| Recruiting | Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunother NCT06731270 | Emory University | Phase 2 |
| Recruiting | Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis NCT06500481 | NRG Oncology | Phase 3 |
| Recruiting | Hippocampal Avoidance in Craniospinal Irradiation for the Treatment of Leptomeningeal Metastases From Breast C NCT06518057 | University of Washington | Phase 2 |
| Recruiting | Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer NCT06616623 | Dwight Owen | Phase 1 |
| Recruiting | Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has NCT06500455 | NRG Oncology | Phase 3 |
| Recruiting | Carfilzomib in Combination With Sotorasib for the Treatment of Patients With KRAS G12C Mutated Advanced or Met NCT06249282 | City of Hope Medical Center | Phase 1 |
| Recruiting | Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform NCT06349642 | Mayo Clinic | — |
| Not Yet Recruiting | Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Ce NCT06067776 | Jonathan Riess | Phase 1 |
| Withdrawn | OT-101 in Combination With Atezolizumab for the Treatment of Metastatic or Recurrent Non-Small Cell Lung Cance NCT05935774 | University of Washington | Phase 2 |
| Unknown | EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer NCT05498389 | Shanghai EpimAb Biotherapeutics Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies NCT05786924 | Institut de Recherches Internationales Servier | Phase 1 / Phase 2 |
| Recruiting | SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Ca NCT05570825 | University of Washington | Phase 2 |
| Recruiting | PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer NCT05234307 | Dwight Owen | Phase 1 |
| Terminated | Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skippin NCT05435846 | Collin Blakely | Phase 1 |
| Unknown | Lazertinib Real-world Observational Study of in Pre-treated EGFR T790M Mutant With Advanced Non-small Cell Lun NCT05377788 | Samsung Medical Center | — |
| Active Not Recruiting | Genetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small C NCT05334329 | University of California, Irvine | Phase 1 |
| Completed | Palliative RadIotherapy of Multiple Metastatic Sites Before First Line of Systemic Therapy With Immune Checkpo NCT05440916 | University Medical Centre Maribor | Phase 2 |
| Recruiting | Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positiv NCT05098210 | Fred Hutchinson Cancer Center | Phase 1 |
| Recruiting | Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Soli NCT05269381 | Mayo Clinic | Phase 1 / Phase 2 |
| Active Not Recruiting | Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With E NCT05256290 | Black Diamond Therapeutics, Inc. | Phase 1 / Phase 2 |
| Terminated | Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous NSCLC NCT04925986 | Sarah Goldberg | Phase 2 |
| Recruiting | Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lu NCT04780568 | Ohio State University Comprehensive Cancer Center | Phase 1 |
| Active Not Recruiting | Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced NCT04514484 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | All-Trans Retinoic Acid (ATRA) and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lu NCT04919369 | Dwight Owen | Phase 1 |
| Active Not Recruiting | Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or NCT04940299 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery NCT04588246 | NRG Oncology | Phase 3 |
| Terminated | Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab NCT04639245 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Withdrawn | Poziotinib and Ramucirumab for the Treatment of EGFR Exon 20 Mutant Stage IV Non-small Cell Lung Cancer NCT05045404 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | Ensartinib, Carboplatin, Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV or Recurrent ALK-Pos NCT04837716 | M.D. Anderson Cancer Center | Phase 1 |
| Recruiting | MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer NCT04762199 | Emory University | Phase 1 |
| Recruiting | Adaptive Radiation Planning for the Reduction of Radiation-Induced Toxicity in Patients With Stage II-IV Non-s NCT04751747 | Rutgers, The State University of New Jersey | N/A |
| Active Not Recruiting | Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth F NCT04285671 | Jonsson Comprehensive Cancer Center | Phase 1 / Phase 2 |
| Terminated | Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases NCT04789668 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Testing the Effects of MK-3475 (Pembrolizumab) With or Without the Usual Chemotherapy Treatment for Patients 7 NCT04533451 | Alliance for Clinical Trials in Oncology | Phase 2 |
| Active Not Recruiting | Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-s NCT04250545 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Ramucirumab and Pembrolizumab for the Treatment of EGFR Mutant Recurrent or Metastatic Non-small Cell Lung Can NCT04120454 | Ohio State University Comprehensive Cancer Center | Phase 2 |
| Active Not Recruiting | Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lun NCT03831932 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Active Not Recruiting | Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCL NCT04227028 | City of Hope Medical Center | Phase 1 |
| Active Not Recruiting | Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors NCT04007744 | Mayo Clinic | Phase 1 |
| Active Not Recruiting | WSD0922-FU for the Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Centr NCT04197934 | Mayo Clinic | Phase 1 |
| Withdrawn | [18F]-AraG for the Detection of T-Cell Activation in Advanced Non-small Cell Lung Cancer Patients Undergoing P NCT04186988 | University of California, Davis | EARLY_Phase 1 |
| Recruiting | PET/CT Changes During Chemoimmunotherapy and Radiation Therapy in Patients With Stage IV Non-small Cell Lung C NCT04151940 | University of Washington | N/A |
| Recruiting | Insomnia in Patients With Metastatic Lung Cancer NCT06472804 | Mayo Clinic | — |
| Active Not Recruiting | Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lun NCT03600701 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and NCT02971501 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease NCT03025256 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-small Cell Lung Cancer That Is Metastatic NCT03225664 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metas NCT02888743 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing the Safety of M6620 (VX-970) When Given With Standard Whole Brain Radiation Therapy for the Treatment NCT02589522 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) M NCT02503722 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or NCT02955290 | Roswell Park Cancer Institute | Phase 1 / Phase 2 |
| Active Not Recruiting | A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors NCT02498613 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Ca NCT02496663 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medication NCT02595866 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies NCT02706392 | Fred Hutchinson Cancer Center | Phase 1 |
| Active Not Recruiting | Pembrolizumab and Stereotactic Body Radiation Therapy or Non-Stereotactic Wide-Field Radiation Therapy in Trea NCT02444741 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Terminated | Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherap NCT02419495 | M.D. Anderson Cancer Center | Phase 1 |